ERBB2 and breast carcinoma: In this study, we produced a defucosylated IgG2a type of anti-HER2 mAb (H2Mab-139-mG2a-f) and evaluated the ability to induce ADCC/CDC in vitro or antitumor efficacy in vivo against HER2-positive and HER2-negative breast cancer cells.